About this trial
Intracranial atherosclerotic disease is an important cause of ischemic stroke, and intracranial stent implantation is increasingly used for patients with severe stenotic lesions. Evaluation of stent patency and detection of in-stent restenosis are essential during follow-up. Digital subtraction angiography (DSA) remains the reference standard for intracranial stent assessment; however, it is an invasive procedure associated with potential complications and radiation exposure. Conventional CT angiography may be limited by stent-related artifacts, including blooming artifact and beam-hardening effects, which can impair accurate evaluation of the stent lumen.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥18 years;
Patients with previously implanted intracranial arterial stents;
Undergoing follow-up CTA examination;
Available imaging data for analysis.
Disqualifiers
Severe motion artifacts;
Poor contrast enhancement;
Incomplete clinical or imaging data.
Trial population
Patients with intracranial arterial stents
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Sensitivity of UHR PCD-CTA for detecting significant in-stent stenosis
Sensitivity of ultra-high-resolution photon-counting detector CT angiography (UHR PCD-CTA) for detecting significant in-stent stenosis (≥50%), using digital subtraction angiography (DSA) as the reference standard.
Secondary outcomes
Diagnostic accuracy of UHR PCD-CTA for detecting significant in-stent stenosis
Diagnostic accuracy of UHR PCD-CTA for detecting significant in-stent stenosis (≥50%), using DSA as the reference standard.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Xin Lou
Lead sponsor
Chinese PLA General Hospital
Sponsor institution